Meriofert Pfs

Follicle-Stimulating Hormone and Luteinising Hormone, the active ingredient in Meriofert Pfs, is a gonadotropin presented as a sterile injectable solution for subcutaneous use. It is employed to treat infertility caused by anovulation, to support controlled ovarian stimulation in assisted reproductive technologies, and to replace deficient hormones in hypogonadotropic hypogonadism.

GNH USA supplies Meriofert Pfs as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality, regulatory compliance and reliable cold‑chain logistics.

Meriofert Pfs is used in reproductive medicine to address disorders of follicular development and hormone deficiency. - Infertility due to anovulation: promotes follicular growth and ovulation to improve chances of conception. - Controlled ovarian stimulation for assisted reproductive technologies: enhances multiple follicle development for IVF or ICSI cycles. - Hypogonadotropic hypogonadism: replaces deficient gonadotropins to restore normal ovarian function.

Adverse reactions to Meriofert Pfs may vary in frequency and severity.

Common Side Effects: - Injection site pain: mild discomfort or erythema at the injection site. - Headache: transient headache reported by some patients. - Nausea: occasional mild nausea following administration. - Ovarian hyperstimulation syndrome (mild): abdominal bloating and mild discomfort.

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome (severe): rapid weight gain, ascites, and respiratory distress. - Thromboembolic events: rare cases of blood clots in veins or arteries. - Allergic reactions: anaphylaxis, urticaria, or angioedema requiring immediate medical attention.

When prescribing Meriofert Pfs, clinicians should consider several safety precautions. - Patient selection: assess baseline ovarian reserve and hormonal profile before initiation. - Monitoring: perform regular ultrasound and estradiol measurements to detect excessive response. - Contraindications: avoid use in active ovarian cysts, uncontrolled thyroid disease, or estrogen‑dependent tumors. - Pregnancy testing: confirm negative pregnancy test prior to starting therapy. - Drug interactions: review concomitant medications that may affect ovarian response. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meriofert Pfs may interact with other agents that influence ovarian response or hormone metabolism.

Major Interactions (Avoid): - Gonadotropin‑releasing hormone (GnRH) antagonists: may blunt the intended ovarian stimulation. - High‑dose estrogen therapy: can suppress endogenous gonadotropin activity and reduce efficacy.

Moderate Interactions (Monitor Closely): - Clomiphene citrate: concurrent use may increase risk of ovarian hyperstimulation. - Aromatase inhibitors: may alter estradiol levels and require dose adjustments. - Anticoagulants: monitor for thrombotic complications if severe ovarian hyperstimulation occurs.